Linda S May-Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10901031/publications.pdf

Version: 2024-02-01

1307594 1588992 9 173 7 8 citations g-index h-index papers 11 11 11 245 docs citations citing authors all docs times ranked

#	Article	IF	Citations
1	Kidney injury-mediated disruption of intestinal lymphatics involves dicarbonyl-modified lipoproteins. Kidney International, 2021, 100, 585-596.	5.2	11
2	Myeloperoxidase-induced modification of HDL by isolevuglandins inhibits paraoxonase-1 activity. Journal of Biological Chemistry, 2021, 297, 101019.	3.4	13
3	Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions., 2020, 205, 107418.		27
4	Engineering the gut microbiota to treat chronic diseases. Applied Microbiology and Biotechnology, 2020, 104, 7657-7671.	3.6	19
5	Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. Journal of Clinical Lipidology, 2020, 14, 293-296.	1.5	2
6	Administration of N-Acyl-Phosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptorâ"/â" Mice Improves Indices of Cardiometabolic Disease. Scientific Reports, 2019, 9, 420.	3.3	28
7	Modified sites and functional consequences of 4-oxo-2-nonenal adducts in HDL that are elevated in familial hypercholesterolemia. Journal of Biological Chemistry, 2019, 294, 19022-19033.	3.4	16
8	Modification by isolevuglandins, highly reactive \hat{I}^3 -ketoaldehydes, deleteriously alters high-density lipoprotein structure and function. Journal of Biological Chemistry, 2018, 293, 9176-9187.	3.4	44
9	Isolevuglandins and cardiovascular disease. Prostaglandins and Other Lipid Mediators, 2018, 139, 29-35.	1.9	12